Alzamend Neuro, Inc. (ALZN) - Q1 2025 (Ended July 31, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 31, 2024. Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing two primary product candidates: AL001 (a lithium-based ionic cocrystal for Alzheimer's, bipolar disorder, MDD, and PTSD) and ALZN002 (an active immunotherapy vaccine for Alzheimer's). The Company has not generated any product revenue to date and relies on equity and debt financing to fund operations. The Company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 (Ended July 31, 2024) | Q1 2024 (Ended July 31, 2023) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(974,411) | $(3,527,766) |
| Loss Per Share (Basic & Diluted) | $(1.25) | $(5.38) |
| Cash and Cash Equivalents (End of Period) | $1,193,950 | $1,695,416 |
| Working Capital | $(1,465,980) Deficiency | Not explicitly stated (Liabilities exceeded Assets) |
| Total Assets | $1,669,852 | $631,588 (Prior Year End) |
| Total Liabilities | $2,882,171 | $3,225,773 (Prior Year End) |
| Stockholders' Deficit | $(1,212,319) | $(2,594,185) (Prior Year End) |
Material Changes vs. Prior Period
- Significant Expense Reduction: Total operating expenses decreased by 73% to $962,405 from $3.5 million in the prior year.
- R&D Expenses: Dropped 91% to $206,571, primarily due to the cessation of clinical trial fees ($0 vs. $1.2 million previously) and reduced professional fees.
- G&A Expenses: Decreased 35% to $755,834, driven by a 78% reduction in stock-based compensation ($81k vs. $369k) and an 84% drop in marketing fees.
- Capital Raising: The Company raised approximately $2.0 million in net proceeds from the issuance of Series A Convertible Preferred Stock during the quarter. This included a $1.0 million tranche (partially paid via debt conversion) and a $1.5 million cash tranche.
- Debt Reduction: A note payable of $300,714 outstanding at the beginning of the period was fully converted into Series B Convertible Preferred Stock, resulting in $0 note payable at period end.
- Reverse Stock Split: A 1-for-10 reverse stock split became effective on July 16, 2024. All share data in the filing has been retroactively adjusted.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for at least one year from the filing date. Cash on hand ($1.2 million) is deemed insufficient to fund planned operations without additional financing.
- Future Financing: The Company is actively pursuing additional capital through the sale of Series A and Series B Convertible Preferred Stock. A Securities Purchase Agreement with Orchid Finance, LLC allows for up to $25 million in potential funding based on milestones and monthly tranches.
- Clinical Development:
- AL001: The Company plans to initiate clinical trials in 2025. It has received "Study May Proceed" letters from the FDA for Bipolar Disorder (BD), Major Depressive Disorder (MDD), and PTSD indications.
- ALZN002: The Company terminated its contract with its previous CRO (Biorasi) in February 2024 and is currently seeking a replacement to continue the Phase I/IIA trial.
- Internal Controls: The Company disclosed that its internal control over financial reporting was not effective due to material weaknesses, specifically regarding insufficient accounting resources and ineffective user access controls. Remediation plans are underway.
- Subsequent Events: Between August 1 and September 10, 2024, the Company sold an additional $4.5 million of Series A Preferred Stock to Orchid, and significant conversions of preferred stock to common stock occurred.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.2 million cash balance against the burn rate of ~$1 million per quarter to confirm the timeline for the next capital raise.
- Financing Milestones: Review the specific milestones required to trigger the remaining tranches of the Orchid Finance agreement (e.g., registration statement effectiveness, CRO partnership).
- CRO Status: Confirm the engagement of a new Contract Research Organization (CRO) for the ALZN002 trial to assess potential delays in clinical timelines.
- Dilution Impact: Analyze the impact of the recent and potential future conversions of Series A and Series B preferred stock and warrant exercises on common share count and ownership dilution.
- Internal Control Remediation: Monitor progress on remediation of material weaknesses in financial reporting to ensure future financial data reliability.